Palvella Therapeutics, Inc. Earnings Per Share (Basic)
Palvella Therapeutics, Inc. (PVLA) reported Earnings Per Share (Basic) of -$1.52 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-04
- Palvella Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$1.52.
- Palvella Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$1.20.
- Palvella Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$1.03.
- Palvella Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-06-30 was -$0.86.
- Palvella Therapeutics, Inc. earnings per share, basic for fiscal 2025 was -$3.71.
- Palvella Therapeutics, Inc. earnings per share, basic for fiscal 2024 was -$7.83, a 457.53% decline from fiscal 2023.
- Palvella Therapeutics, Inc. earnings per share, basic for fiscal 2023 was $2.19.
- Palvella Therapeutics, Inc. earnings per share, basic for fiscal 2022 was -$0.45.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.52 10-Q · filed 2026-08-04 | -$2.74 10-Q · filed 2026-08-04 | ||||||
| 2026-03-31 | -$1.20 10-Q · filed 2026-05-07 | |||||||
| 2025-12-31 | -$3.71 10-K · filed 2026-03-31 | |||||||
| 2025-09-30 | -$1.03 10-Q · filed 2025-11-12 | -$1.88 derived: net income ÷ weighted average shares · filed 2026-08-04 | -$2.63 10-Q · filed 2025-11-12 | -$3.53 derived: net income ÷ weighted average shares · filed 2026-08-04 | ||||
| 2025-06-30 | -$0.86 10-Q · filed 2026-08-04 | -$1.60 10-Q · filed 2026-08-04 | -$2.46 derived: net income ÷ weighted average shares · filed 2026-08-04 | -$4.08 derived: net income ÷ weighted average shares · filed 2026-08-04 | ||||
| 2025-03-31 | -$0.74 10-Q · filed 2026-05-07 | -$1.58 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$3.39 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$5.05 derived: net income ÷ weighted average shares · filed 2026-05-07 | ||||
| 2024-12-31 | -$0.94 derived: net income ÷ weighted average shares · filed 2026-03-31 | -$3.86 derived: net income ÷ weighted average shares · filed 2026-03-31 | -$6.18 derived: net income ÷ weighted average shares · filed 2026-03-31 | -$7.83 10-K · filed 2026-03-31 | ||||
| 2024-09-30 | -$3.94 10-Q · filed 2025-11-12 | -$2.19 10-Q · filed 2024-11-13 | -$6.40 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$7.95 10-Q · filed 2025-11-12 | -$8.84 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | -$2.47 10-Q · filed 2025-08-14 | -$2.76 10-Q · filed 2024-08-14 | -$4.01 10-Q · filed 2025-08-14 | -$6.69 10-Q · filed 2024-08-14 | ||||
| 2024-03-31 | -$1.54 10-Q · filed 2025-05-15 | -$3.95 10-Q · filed 2024-05-15 | ||||||
| 2023-12-31 | $2.19 10-K · filed 2025-03-31 | -$0.27 10-K · filed 2024-03-29 | ||||||
| 2023-09-30 | -$8.70 10-Q · filed 2024-11-13 | -$0.11 10-Q · filed 2023-11-14 | -$18.33 10-Q · filed 2024-11-13 | -$0.23 10-Q · filed 2023-11-14 | ||||
| 2023-06-30 | $3.63 10-Q · filed 2024-08-14 | $0.05 10-Q · filed 2023-08-10 | -$9.08 10-Q · filed 2024-08-14 | -$0.11 10-Q · filed 2023-08-10 | ||||
| 2023-03-31 | -$14.15 10-Q · filed 2024-05-15 | -$0.18 10-Q · filed 2023-05-11 | ||||||
| 2022-12-31 | -$0.45 10-K · filed 2024-03-29 | |||||||
| 2022-09-30 | -$0.13 10-Q · filed 2023-11-14 | -$0.34 10-Q · filed 2023-11-14 | ||||||
| 2022-06-30 | -$0.14 10-Q · filed 2023-08-10 | -$0.21 10-Q · filed 2023-08-10 | ||||||
| 2022-03-31 | -$0.07 10-Q · filed 2023-05-11 | |||||||
| 2021-12-31 | -$0.71 10-K · filed 2023-03-31 | |||||||
| 2021-09-30 | -$0.24 10-Q · filed 2022-11-04 | -$0.58 10-Q · filed 2022-11-04 | ||||||
| 2021-06-30 | -$0.25 10-Q · filed 2022-08-04 | -$0.33 10-Q · filed 2022-08-04 | ||||||
| 2021-03-31 | -$0.07 10-Q · filed 2022-05-11 | |||||||
| 2020-12-31 | -$0.68 10-K · filed 2022-03-02 | |||||||
| 2020-09-30 | -$0.26 10-Q · filed 2021-11-02 | -$0.42 10-Q · filed 2021-11-02 | ||||||
| 2020-06-30 | -$0.09 10-Q · filed 2021-08-05 | -$0.16 10-Q · filed 2021-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |